Silva BS, Yamamoto FP, Corręa-Pontes
FS, Cury SE, Fonseca FP, Pontes HA, Pinto-Júnior D. TWIST and p-Akt immunoexpression in normal oral epithelium, oral dysplasia
and in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2012 Jan 1;17 (1):e29-34.
doi:10.4317/medoral.17344
1. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their correspondingsquamous-cell
carcinomas. Br J Cancer. 2009;100:1128-34.
http://dx.doi.org/10.1038/sj.bjc.6604967
PMid:19293805 PMCid:2669983
2. Pitiyage G, Tilakaratne
WM, Tavassoli M, Warnakulasuriya
S. Molecular markers in oral epithelial dysplasia: review. J Oral Pathol Med. 2009;38:737-52.
http://dx.doi.org/10.1111/j.1600-0714.2009.00804.x
3. Lee JJ, Hung HC, Cheng SJ, Chiang CP, Liu BY, Yu CH,
et al. Factors associated with underdiagnosis from incisional biopsy of oralleukoplakic
lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:217-25.
http://dx.doi.org/10.1016/j.tripleo.2007.02.012
PMid:17560138
4. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially
malignant disorders of the oral mucosa. J Oral Pathol
Med. 2007;36:575-80.
http://dx.doi.org/10.1111/j.1600-0714.2007.00582.x
5. Kramer IR, Lucas RB, Pindborg
JJ, Sobin LH. Definition of leukoplakia
and related lesions: an aid to studies on oral precancer.
Oral Surg Oral Med OralPathol. 1978;46:518-39.
http://dx.doi.org/10.1016/0030-4220(78)90383-3
6. Smith J, Rattay T, McConkey C, Helliwell T, Mehanna H. Biomarkers in dysplasia of the oral cavity: a
systematic review. Oral Oncol.
2009;45:647-53.
http://dx.doi.org/10.1016/j.oraloncology.2009.02.006
PMid:19442563
7. Karabulut A, Reibel J, Therkildsen MH, Praetorius F,
Nielsen HW, Dabelsteen E. Observer variability in the
histologic assessment of oral premalignant lesions. J
Oral Pathol Med. 1995;24:198-200.
http://dx.doi.org/10.1111/j.1600-0714.1995.tb01166.x
PMid:7616457
8. Chimenos-Küstner E, Font-Costa I, López-López J. Oral cancer risk and molecular markers. Med
Oral Patol Oral Cir Bucal.2004;9:381-4,
377-80.
9. Pontes
HA, de Aquino Xavier FC, da Silva TS, Fonseca FP, Paiva
HB, Pontes FS, et al. Metallothionein
and p-Akt proteins in oral dysplasia andin oral squamous cell
carcinoma: an immunohistochemical study. J Oral Pathol Med. 2009;38:644-50.
http://dx.doi.org/10.1111/j.1600-0714.2009.00787.x
10. Watanabe S, Sato K, Okazaki Y, Tonogi M, Tanaka Y, Yamane GY. Activation of
PI3K-AKT pathway in oral epithelial dysplasia and early cancer of tongue. BullTokyo Dent Coll. 2009;50:125-33.
http://dx.doi.org/10.2209/tdcpublication.50.125
PMid:19887755
11. Wu HT, Ko SY, Fong JH,
Chang KW, Liu TY, Kao SY. Expression of phosphorylated
Akt in oral carcinogenesis and its induction by nicotine
and alkalinestimulation. J Oral Pathol Med. 2009;38:206-13.
http://dx.doi.org/10.1111/j.1600-0714.2008.00659.x
12. Sun M, Paciga JE, Feldman
RI, Yuan Z, Coppola D, Lu YY, et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breastcancer,
regulates and is induced by estrogen receptor alpha (ERalpha) viainteraction between ERalpha and PI3K. Cancer Res. 2001;61:5985-91.
PMid:11507039
13. Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan XY, et al. Significance of TWIST expression and
its association with E-cadherin inbladder
cancer. Hum Pathol. 2007;38:598-606.
http://dx.doi.org/10.1016/j.humpath.2006.10.004
PMid:17258791
14. Xie F,
Li K, Ouyang X. Twist, an independent prognostic
marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinomapatients.
Clin Exp Metastasis. 2009;26:1025-32.
http://dx.doi.org/10.1007/s10585-009-9292-5
15. Ou DL, Chien
HF, Chen CL, Lin TC, Lin LI. Role of Twist in head and neck carcinoma with
lymph node metastasis. Anticancer Res. 2008;28:1355-9.
PMid:18505078
16. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells
leading to increased migration,invasion,
and resistance to paclitaxel. Cancer Res. 2007;67:1979-87.
http://dx.doi.org/10.1158/0008-5472.CAN-06-1479
PMid:17332325
17. Barnes L EJ, Reichart PA, Sidranskiy
D. World Health Organization Classification of Tumours,
Pathology and Genetics of Head and Neck Tumours. 1 th. LYON; IARC Press: 2005.
18. Mithani SK, Mydlarz WK,
Grumbine FL, Smith IM, Califano
JA. Molecular genetics of premalignant oral lesions.
Oral Dis. 2007;13:126-33.
http://dx.doi.org/10.1111/j.1601-0825.2006.01349.x
PMid:17305612
19. Crissman JD, Zarbo RJ. Dysplasia, in situ carcinoma, and progression to invasive squamous cell carcinoma of the upper aerodigestive
tract.Am J SurgPathol.
1989;13 Suppl 1:5-16.
PMid:2699168
20. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin
switching. J Cell Sci. 2008;121:727-35.
http://dx.doi.org/10.1242/jcs.000455
PMid:18322269
21. Luo GQ, Li JH, Wen JF,
Zhou YH, Hu YB, Zhou JH. Effect and
mechanism of the Twist gene on invasion and metastasis of gastric carcinoma cells.World JGastroenterol.
2008;14:2487-93.
http://dx.doi.org/10.3748/wjg.14.2487
PMid:18442194 PMCid:2708358
22. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW. Significance
of TWIST and E-cadherin expression in the metastatic
progression of prostatic cancer.Histopathology.
2007;50:648-58.
http://dx.doi.org/10.1111/j.1365-2559.2007.02665.x
PMid:17394502
23. Hotz B, Arndt M, Dullat
S, Bhargava S, Buhr HJ, Hotz HG. Epithelial to mesenchymal
transition: expression of the regulators snail, slug, and twist inpancreatic cancer. Clin Cancer
Res. 2007;13:4769-76.
http://dx.doi.org/10.1158/1078-0432.CCR-06-2926
PMid:17699854
24. Shibata K, Kajiyama H, Ino K, Terauchi M, Yamamoto E, Nawa A, et al. Twist
expression in patients with cervical cancer is associated withpoor
disease outcome. Ann Oncol. 2008;19:81-5.
http://dx.doi.org/10.1093/annonc/mdm344
PMid:17925286
25. Fondrevelle ME, Kantelip
B, Reiter RE, Chopin DK, Thiery JP, Monnien F, et al. The expression of Twist has an impact on
survival inhuman bladder cancer and is influenced by the smoking status. Urol Oncol. 2009;27:268-76.
http://dx.doi.org/10.1016/j.urolonc.2007.12.012
PMid:18440840
26. Hong KO, Kim JH, Hong JS, Yoon HJ, Lee JI, Hong SP, et al. Inhibition of Akt activity induces the mesenchymal-to-epithelial
reverting transition with restoring E-cadherin
expression in KB and KOSCC-25B oral squamous cell
carcinoma cells. J Exp Clin Cancer Res. 2009;28:28.
http://dx.doi.org/10.1186/1756-9966-28-28
27. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells
by stromal-derived factor-1alpha (CXCL12)increases
endothelial adhesion and transendothelial migration:
role of MEK/ERKsignaling pathway-dependent NF-kappaB activation. Cancer Res. 2005;65:9891-8.
http://dx.doi.org/10.1158/0008-5472.CAN-05-1293
PMid:16267013
28. Onoue T, Uchida D, Begum NM, Tomizuka
Y, Yoshida H, Sato M. Epithelial-mesenchymal transition
induced by the stromal cell-derivedfactor-1/CXCR4
system in oral squamous cell carcinoma cells. Int J Oncol. 2006;29:1133-8.
PMid:17016644
29. Li X, Stark GR. NFkappaB-dependent signaling
pathways. Exp Hematol. 2002;30:285-96.
http://dx.doi.org/10.1016/S0301-472X(02)00777-4
30. Zhang X, Wang Q, Ling MT, Wong YC, Leung SC, Wang X.
Anti-apoptotic role of TWIST and its association with Akt
pathway in mediating taxol resistance innasopharyngeal carcinoma cells. Int
J Cancer. 2007;120:1891-8.
http://dx.doi.org/10.1002/ijc.22489
PMid:17230521
31. Amornphimoltham P, Sriuranpong
V, Patel V, Benavides F, Conti CJ, Sauk J, et al. Persistent activation of the Akt pathwayin head and neck squamous cell carcinoma: a potential target for UCN-01. ClinCancer Res. 2004;10:4029-37.
http://dx.doi.org/10.1158/1078-0432.CCR-03-0249
PMid:15217935